WO2001085981A3 - Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis - Google Patents
Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis Download PDFInfo
- Publication number
- WO2001085981A3 WO2001085981A3 PCT/US2001/014364 US0114364W WO0185981A3 WO 2001085981 A3 WO2001085981 A3 WO 2001085981A3 US 0114364 W US0114364 W US 0114364W WO 0185981 A3 WO0185981 A3 WO 0185981A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- regeneration
- arginase
- nervous system
- neuronal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60137414T DE60137414D1 (en) | 2000-05-05 | 2001-05-04 | COMPOSITIONS FOR STIMULATING REGENERATION AND RECONSTITUTION OF THE NERVOUS SYSTEM BY REGULATING THE ARGINASE 1 AND POLYAMINE SYNTHESIS |
AU2001259453A AU2001259453B2 (en) | 2000-05-05 | 2001-05-04 | Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis |
CA002408255A CA2408255A1 (en) | 2000-05-05 | 2001-05-04 | Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis |
US10/275,513 US7741310B2 (en) | 2000-05-05 | 2001-05-04 | Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis |
EP01932977A EP1278537B1 (en) | 2000-05-05 | 2001-05-04 | Compositions for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
AU5945301A AU5945301A (en) | 2000-05-05 | 2001-05-04 | Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
HK03105409.1A HK1054680A1 (en) | 2000-05-05 | 2003-07-25 | Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
US12/613,310 US8673594B2 (en) | 2000-05-05 | 2009-11-05 | Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20230700P | 2000-05-05 | 2000-05-05 | |
US60/202,307 | 2000-05-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10275513 A-371-Of-International | 2001-05-04 | ||
US12/613,310 Division US8673594B2 (en) | 2000-05-05 | 2009-11-05 | Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001085981A2 WO2001085981A2 (en) | 2001-11-15 |
WO2001085981A3 true WO2001085981A3 (en) | 2002-03-14 |
Family
ID=22749330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/014364 WO2001085981A2 (en) | 2000-05-05 | 2001-05-04 | Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
Country Status (9)
Country | Link |
---|---|
US (2) | US7741310B2 (en) |
EP (1) | EP1278537B1 (en) |
AT (1) | ATE420656T1 (en) |
AU (2) | AU2001259453B2 (en) |
CA (1) | CA2408255A1 (en) |
DE (1) | DE60137414D1 (en) |
ES (1) | ES2322332T3 (en) |
HK (1) | HK1054680A1 (en) |
WO (1) | WO2001085981A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7211602B2 (en) | 2001-11-16 | 2007-05-01 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
EP1448183A2 (en) * | 2001-11-16 | 2004-08-25 | ALS Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
PT1583541E (en) * | 2002-11-20 | 2011-04-06 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
CA2836155A1 (en) | 2004-10-29 | 2006-05-11 | Board Of Trustees Of Michigan State University | Protection against herbivores |
WO2007014156A2 (en) * | 2005-07-21 | 2007-02-01 | Buck Institute For Age Research | Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease |
EP2012819A2 (en) | 2006-03-30 | 2009-01-14 | The Research Foundation Of the City university of New York | Stimulation of neuron regeneration by secretory leukocyte protease inhibitor |
WO2008086573A1 (en) * | 2007-01-19 | 2008-07-24 | Howard Florey Institute Of Experimental Physiology And Medicine | Use of galanin in a method of treating neurodegenerative diseases or conditions |
WO2009020601A2 (en) * | 2007-08-03 | 2009-02-12 | Cornell University | Atf4 inhibitors and their use for neural protection, repair, regeneration, and plasticity |
US20110016548A1 (en) * | 2009-07-16 | 2011-01-20 | University Of Southern California | Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems |
US11268655B2 (en) | 2018-01-09 | 2022-03-08 | Cryoport, Inc. | Cryosphere |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993001300A1 (en) * | 1991-07-10 | 1993-01-21 | Regeneron Pharmaceuticals, Inc. | Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules |
US5395612A (en) * | 1990-03-27 | 1995-03-07 | Cornell Research Foundation, Inc. | Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist |
FR2717496A1 (en) * | 1994-03-18 | 1995-09-22 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
WO1997001352A1 (en) * | 1995-06-27 | 1997-01-16 | Research Foundation Of Cuny, Hunter College | Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof |
WO1997011965A1 (en) * | 1995-09-28 | 1997-04-03 | Amgen Inc. | Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
WO1997030167A1 (en) * | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
WO1997034567A2 (en) * | 1996-03-19 | 1997-09-25 | Amgen Inc. | Method for treating huntington's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
WO1997039629A1 (en) * | 1996-04-25 | 1997-10-30 | Genetic Therapy, Inc. | Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor |
WO1999014235A1 (en) * | 1997-09-16 | 1999-03-25 | Washington University | Persephin and related growth factors |
WO1999043345A1 (en) * | 1998-02-26 | 1999-09-02 | Eisai Co., Ltd. | Amino acid degrading enzymes modulate cell death |
WO2000018799A1 (en) * | 1998-09-29 | 2000-04-06 | Washington University | Artemin, a novel neurotrophic factor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2300092A (en) | 1991-07-03 | 1993-02-11 | Nathan E. Scott | Prostaglandin e2 treatment of impotence |
US6096716A (en) * | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
US5990168A (en) | 1996-04-18 | 1999-11-23 | Alberta Cancer Board | Methods and compositions for the treatment of ataxia telangiectasia |
WO1999019295A1 (en) * | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
US6708712B2 (en) | 2001-10-04 | 2004-03-23 | Illinois Tool Works Inc. | Pressure regulator utilizing a disc spring |
US7211602B2 (en) * | 2001-11-16 | 2007-05-01 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
WO2003073990A2 (en) * | 2002-03-01 | 2003-09-12 | Children's Hospital Medical Center | Treatment for asthma or allergies |
-
2001
- 2001-05-04 AU AU2001259453A patent/AU2001259453B2/en not_active Ceased
- 2001-05-04 CA CA002408255A patent/CA2408255A1/en not_active Abandoned
- 2001-05-04 ES ES01932977T patent/ES2322332T3/en not_active Expired - Lifetime
- 2001-05-04 AT AT01932977T patent/ATE420656T1/en not_active IP Right Cessation
- 2001-05-04 US US10/275,513 patent/US7741310B2/en not_active Expired - Fee Related
- 2001-05-04 EP EP01932977A patent/EP1278537B1/en not_active Expired - Lifetime
- 2001-05-04 AU AU5945301A patent/AU5945301A/en active Pending
- 2001-05-04 WO PCT/US2001/014364 patent/WO2001085981A2/en active Application Filing
- 2001-05-04 DE DE60137414T patent/DE60137414D1/en not_active Expired - Lifetime
-
2003
- 2003-07-25 HK HK03105409.1A patent/HK1054680A1/en unknown
-
2009
- 2009-11-05 US US12/613,310 patent/US8673594B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5395612A (en) * | 1990-03-27 | 1995-03-07 | Cornell Research Foundation, Inc. | Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist |
WO1993001300A1 (en) * | 1991-07-10 | 1993-01-21 | Regeneron Pharmaceuticals, Inc. | Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules |
FR2717496A1 (en) * | 1994-03-18 | 1995-09-22 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
WO1997001352A1 (en) * | 1995-06-27 | 1997-01-16 | Research Foundation Of Cuny, Hunter College | Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof |
WO1997011965A1 (en) * | 1995-09-28 | 1997-04-03 | Amgen Inc. | Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
WO1997030167A1 (en) * | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
WO1997034567A2 (en) * | 1996-03-19 | 1997-09-25 | Amgen Inc. | Method for treating huntington's disease using glial cell line-derived neurotrophic factor (gdnf) protein product |
WO1997039629A1 (en) * | 1996-04-25 | 1997-10-30 | Genetic Therapy, Inc. | Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor |
WO1999014235A1 (en) * | 1997-09-16 | 1999-03-25 | Washington University | Persephin and related growth factors |
WO1999043345A1 (en) * | 1998-02-26 | 1999-09-02 | Eisai Co., Ltd. | Amino acid degrading enzymes modulate cell death |
WO2000018799A1 (en) * | 1998-09-29 | 2000-04-06 | Washington University | Artemin, a novel neurotrophic factor |
Non-Patent Citations (13)
Title |
---|
DAS S ET AL: "DEXAMETHASONE AND DIBUTYRYL CYCLIC AMP INDUCE THE EXPRESSION OF ALPHA-1 ANTICHYMOTRYPSIN IN RAT ASTROCYTES IMPLICATIONS FOR ALZHEIMER'S DISEASE", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 17, no. 1-2, 1991, pages 1072, XP002183003, ISSN: 0190-5295 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, MENA MARIA ANGELES ET AL: "Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: Prevention of cell death by dibutyryl cyclic AMP.", XP002183005, Database accession no. PREV199698566649 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 1999 (1999-01-01), CAI DONGMING ET AL: "Prior exposure to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin via a cAMP-dependent mechanism.", XP002183593, Database accession no. PREV199900130623 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 1999 (1999-01-01), PEREZ-NAVARRO E ET AL: "Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo.", XP002183007, Database accession no. PREV199900092414 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 1999 (1999-05-01), ROSENBLAD CARL ET AL: "Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.", XP002183006, Database accession no. PREV199900257451 * |
ESCH F ET AL: "PURIFICATION OF A MULTIPOTENT ANTIDEATH ACTIVITY FROM BOVINE LIVER AND ITS IDENTIFICATION AS ARGINASE: NITRIC OXIDE-INDEPENDENT INHIBITION OF NEURONAL APOPTOSIS", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 18, no. 11, 1 June 1998 (1998-06-01), pages 4083 - 4095, XP002920233, ISSN: 0270-6474 * |
EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 11, no. 1, January 1999 (1999-01-01), pages 241 - 249, ISSN: 0953-816X * |
EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 11, no. 5, May 1999 (1999-05-01), pages 1554 - 1566, ISSN: 0953-816X * |
JOURNAL OF NEUROCHEMISTRY, vol. 65, no. 6, 1995, pages 2612 - 2620, ISSN: 0022-3042 * |
LINDVALL OLLE ET AL: "Clinical application of cell transplantation and neurotrophic factors in CNS disorders.", CURRENT OPINION IN NEUROBIOLOGY, vol. 4, no. 5, 1994, pages 752 - 757, XP001031365, ISSN: 0959-4388 * |
MOHAJERI M HASAN ET AL: "Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis.", HUMAN GENE THERAPY, vol. 10, no. 11, 20 July 1999 (1999-07-20), pages 1853 - 1866, XP002183001, ISSN: 1043-0342 * |
NEURON, vol. 22, no. 1, January 1999 (1999-01-01), pages 89 - 101, ISSN: 0896-6273 * |
PELLEYMOUNTER MARY ANN ET AL: "The effects of intraseptal BDNF on cognition in rats with MS/DB lesions.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 18, no. 1-2, 1992, 22nd Annual Meeting of the Society for Neuroscience;Anaheim, California, USA; October 25-30, 1992, pages 629, XP002183002, ISSN: 0190-5295 * |
Also Published As
Publication number | Publication date |
---|---|
AU5945301A (en) | 2001-11-20 |
WO2001085981A2 (en) | 2001-11-15 |
HK1054680A1 (en) | 2003-12-12 |
ATE420656T1 (en) | 2009-01-15 |
US7741310B2 (en) | 2010-06-22 |
AU2001259453B2 (en) | 2006-08-31 |
EP1278537B1 (en) | 2009-01-14 |
DE60137414D1 (en) | 2009-03-05 |
ES2322332T3 (en) | 2009-06-19 |
US20100216710A1 (en) | 2010-08-26 |
EP1278537A2 (en) | 2003-01-29 |
US8673594B2 (en) | 2014-03-18 |
CA2408255A1 (en) | 2001-11-15 |
US20030215428A1 (en) | 2003-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002045749A3 (en) | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 | |
WO1999045949A3 (en) | Use of follistatin to modulate gdf-8 and bmp-11 | |
ATE275415T1 (en) | COMPOSITION CONTAINING A MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) INHIBITOR WHICH CONTAINS AN ALTERED OR MUTATED FORM OF MAG | |
CY1123341T1 (en) | NON-SELECTIVE CATION CHANNEL IN NEURON CELLS AND CHANNEL-BLOCKING COMPOUNDS FOR USE IN THE THERAPEUTIC TREATMENT OF CEREBRAL EDITION | |
WO2001085981A3 (en) | Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis | |
HUP0203863A2 (en) | Nogo receptor-mediated blockade of axonal growth | |
WO2002036829A3 (en) | Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries | |
WO2004096245A3 (en) | Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration | |
PA8468501A1 (en) | HETERO-CYCLIC COMPOUNDS AS ROTHAMASE ENZYME INHIBITORS | |
HUP0303900A2 (en) | New use of artemin, a member of the gdnf ligand family | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2007092165A3 (en) | Compositions and methods for enhancing neuronal plasticity and regeneration | |
WO2004021980A3 (en) | Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation | |
WO2005025502A3 (en) | A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration | |
WO2005061002A3 (en) | Composition and methods for modulating cns activity | |
WO2001042784A3 (en) | Methods for screening compounds active on neurons | |
WO2006072792A3 (en) | Compounds which bind to the active site of protein kinase enzymes | |
WO2004110354A3 (en) | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis | |
WO2004016751A3 (en) | Methods of treating neurodegenerative diseases | |
WO2003030836A3 (en) | Neuronal regeneration | |
WO2022235551A3 (en) | Fc-fusion protein therapeutic for the treatment of pancreatitis | |
WO2003037920A3 (en) | Enzyme-deficient c3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration | |
GEP20063859B (en) | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | |
PT1255734E (en) | DERIVATIVES OF ISATIN WITH NEUROTHERAPIC ACTIVITY | |
WO2007008690A3 (en) | Methods for monitoring neuroinflammatory destruction of neurons and for treating diseases having an inflammatory component related to phospholipase a2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2408255 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001259453 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001932977 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001932977 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10275513 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |